Our Story

Since 2002, Lilly Ventures has
focused its investments in
great companies with
compelling life science
innovations that have the
potential to create a
pipeline of life-changing
medicines. We partner actively
with our portfolio company
management teams and
provide intellectual, as
well as financial, resources
to accelerate the path to
success.

Our Team

Our collaborative partnership
leverages the collective
experience, deep expertise,
and networks of our
investment professionals for
the benefit of our portfolio
companies.

Cavion’s T-Type Calcium Channel Modulator CX-8998 is Superior to Current Standard of Care in Suppressing Absence Seizures in a Genetic Epilepsy Model
November 5, 2018

Cavion’s T-Type Calcium Channel Modulator CX-8998 is Superior to Current Standard of Care in Suppressing Absence Seizures in a Genetic Epilepsy Model

view full story

Aileron Therapeutics Appoints Vojislav Vukovic, MD, PhD, as Chief Medical Officer
November 5, 2018

Aileron Therapeutics Appoints Vojislav Vukovic, MD, PhD, as Chief Medical Officer

view full story

Aileron Therapeutics Announces Clinical Trial Collaboration with Dana-Farber/Boston Children’s Cancer and Blood Disorders Center
November 1, 2018

Aileron Therapeutics Announces Clinical Trial Collaboration with Dana-Farber/Boston Children’s Cancer and Blood Disorders Center

view full story

Aeglea BioTherapeutics Announces Positive Interim Clinical Data for Pegzilarginase in Advanced Melanoma Patients at the European Society for Medical Oncology 2018 Congress
October 22, 2018

Aeglea BioTherapeutics Announces Positive Interim Clinical Data for Pegzilarginase in Advanced Melanoma Patients at the European Society for Medical Oncology 2018 Congress

view full story

Aeglea BioTherapeutics Announces New Positive Interim Clinical Data and Improvements in Disease Manifestations for Ongoing Phase 1/2 Trial of Pegzilarginase in Patients with Arginase 1 Deficiency
October 17, 2018

Aeglea BioTherapeutics Announces New Positive Interim Clinical Data and Improvements in Disease Manifestations for Ongoing Phase 1/2 Trial of Pegzilarginase in Patients with Arginase 1 Deficiency

view full story

Sutro’s STRO-001 Receives U.S. FDA Orphan Drug Designation for Treatment of Multiple Myeloma
October 12, 2018

Sutro’s STRO-001 Receives U.S. FDA Orphan Drug Designation for Treatment of Multiple Myeloma

view full story

Cavion Announces Promising Phase 2 Data for Essential Tremor in T-CALM Proof-of-Concept Study
October 5, 2018

Cavion Announces Promising Phase 2 Data for Essential Tremor in T-CALM Proof-of-Concept Study

view full story

Nimbus Therapeutics Names Jeb Keiper as President and Chief Executive Officer
October 4, 2018

Nimbus Therapeutics Names Jeb Keiper as President and Chief Executive Officer

view full story

Cavion to Announce Results of its Phase 2 Essential Tremor Clinical Trial
October 4, 2018

Cavion to Announce Results of its Phase 2 Essential Tremor Clinical Trial

view full story

FDA Grants Rare Pediatric Disease Designation to Pegzilarginase for Arginase 1 Deficiency
October 1, 2018

FDA Grants Rare Pediatric Disease Designation to Pegzilarginase for Arginase 1 Deficiency

view full story

Protagonist Therapeutics Announces Fast Track Designation Granted by U.S. FDA to Hepcidin Mimetic PTG-300
September 27, 2018

Protagonist Therapeutics Announces Fast Track Designation Granted by U.S. FDA to Hepcidin Mimetic PTG-300

view full story

Sutro Biopharma Announces $85.0 Million Initial Public Offering
September 26, 2018

Sutro Biopharma Announces $85.0 Million Initial Public Offering

view full story

Dr. Jared Gollob Joins Kymera Therapeutics as Chief Medical Officer
September 20, 2018

Dr. Jared Gollob Joins Kymera Therapeutics as Chief Medical Officer

view full story

Cavion Appoints Julia P. Gregory Executive Chair
September 11, 2018

Cavion Appoints Julia P. Gregory Executive Chair

view full story

Aileron Therapeutics Announces the Appointment of Dr. Manuel Aivado as Chief Executive Officer
September 6, 2018

Aileron Therapeutics Announces the Appointment of Dr. Manuel Aivado as Chief Executive Officer

view full story

Aeglea Announces Positive Interim Clinical Data and Completion of Enrollment for Ongoing Phase 1-2 Trial of Pegzilarginase in Patients with Arginase 1 Deficiency
September 4, 2018

Aeglea Announces Positive Interim Clinical Data and Completion of Enrollment for Ongoing Phase 1-2 Trial of Pegzilarginase in Patients with Arginase 1 Deficiency

view full story

FDA Grants Orphan Drug Designation to Surface Oncology’s SRF231 for the Treatment of Multiple Myeloma
July 30, 2018

FDA Grants Orphan Drug Designation to Surface Oncology’s SRF231 for the Treatment of Multiple Myeloma

view full story

Sutro Biopharma Collaborates with Merck to Develop Therapeutics for Cancer and Autoimmune Disorders
July 24, 2018

Sutro Biopharma Collaborates with Merck to Develop Therapeutics for Cancer and Autoimmune Disorders

view full story

Aeglea BioTherapeutics Appoints Dr. Anthony G. Quinn as President and Chief Executive Officer
July 19, 2018

Aeglea BioTherapeutics Appoints Dr. Anthony G. Quinn as President and Chief Executive Officer

view full story

Aeglea BioTherapeutics Appoints Dr. Bryan Lawlis to Board of Directors
July 16, 2018

Aeglea BioTherapeutics Appoints Dr. Bryan Lawlis to Board of Directors

view full story

Nimbus Therapeutics Names Adrian Ray, Ph.D., as Senior Vice President of Discovery Biology
July 9, 2018

Nimbus Therapeutics Names Adrian Ray, Ph.D., as Senior Vice President of Discovery Biology

view full story

Protagonist Announces Phase 1 and Pre-clinical Data on Hepcidin Mimetic PTG-300 Presented at European Hematology Association Annual Meeting
June 18, 2018

Protagonist Announces Phase 1 and Pre-clinical Data on Hepcidin Mimetic PTG-300 Presented at European Hematology Association Annual Meeting

view full story

Surface Oncology Announces Initiation of Phase I Clinical Trial of SRF373 / NZV930
June 12, 2018

Surface Oncology Announces Initiation of Phase I Clinical Trial of SRF373 / NZV930

view full story

Nimbus Therapeutics Announces $65 Million in New Financing to Accelerate Pipeline Progress and Expand Discovery Efforts
June 5, 2018

Nimbus Therapeutics Announces $65 Million in New Financing to Accelerate Pipeline Progress and Expand Discovery Efforts

view full story